Obesity prevalence is rising sharply across APAC, with rates from 14% in India to over 58% in Pakistan, yet only 1.4% of global obesity trials enroll from the region. IQVIA surveyed 138 sites in 10 countries, finding experienced investigators and strong patient pools, but barriers like strict eligibility, visit frequency, and concerns over drug side effects. BMI and waist circumference remain key diagnostic tools, with semaglutide and liraglutide widely used. Despite reimbursement gaps and side-effect concerns, APAC shows strong potential for trial expansion, offering diverse populations and high unmet medical need.

Join for free to read